Continuing Education Credits (CME, NSGC, and P.A.C.E.®)


ASHG 2020 OnDemand
Date of Release: October 27, 2020
Expiration Date for Claiming Education Credits (CME, NSGC, P.A.C.E.®): October 25, 2021, 5:00 EST 

Education Credits and Fees

If not purchased during registration, this fee can be paid by calling ASHG’s Registration Call Center at 774-247-4003.

CME Credits (AMA PRA Category 1 Credit™) $50
NSGC CEU Credits for Genetic Counselors $50
P.A.C.E.® CEUs for Laboratory Directors $50


The American Society of Human Genetics (ASHG) Annual Meeting is a forum for the education of physicians in the field of genetics. By attending invited sessions, interactive workshops, and plenary and platform presentations physicians will receive both a broad overview of the field and information about the most recent, detailed research on the topic of the session. By attending any of the virtual (other) or on demand (enduring) activities, physicians will better understand the basic science that underlies clinical practice.

Statement of Need

It is important that physicians comprehend the basic science that underlies clinical medicine. The American Society of Human Genetics Annual Meeting is the premier venue for this educational opportunity. Physicians, genetic counselors, laboratory geneticists, and clinical geneticists learn about the most up-to-date, cutting-edge discoveries regarding genetics.

Target Audience

This meeting is targeted to research scientists, clinical and laboratory practitioners, and others interested in the field of human genetics. The program is varied so that participants may select from several concurrent sessions, those that fit their specialized research interests and clinical practice applications.

ASHG Annual Meeting attendees include:

  • Scientists/Researchers
  • Laboratory geneticists, directors, technicians, and technologists
  • Educators
  • Medical and clinical geneticists
  • Physicians of all specialties with an interest in genetics, genomics, and the genetic basis of disease
  • Genetic counselors
  • Nurses
  • Biotechnology and pharmaceutical development professionals
  • Fellows, trainees, and students


Invited Sessions CME | P.A.C.E.® | NSGC
Variant-to-Function Coupling: Understanding Non-coding Variation in Human Disease 1.50
Re-evaluating Penetrance: Modifiers, Mechanisms and Implications for Genetic Testing 1.50
Asthma in Diverse Populations 1.50
Underrepresented Populations in Genomics: Health, Evolutionary, and Ethical Aspects 1.50
The History and Future of Protections Against Genetic Discrimination 1.50
Scalable Functional Genomics Approaches to Dissect Genetic Architecture 1.50
Extending Phenotype-Genotype Correlations to the Fetus: Integrating Genetics, Imaging, and the Electric Health Record 1.50
Evolutionary Genomic Medicine 1.50
Indigenous Biobanking: Global Perspectives on Keeping Our Genomic Data Local 1.50
Using Novel Analytical Approaches to Identify High-Risk Genes in Next-Generation Sequencing of Multiplex Pedigrees 1.50
Epi-Phenotyping of Neurodevelopmental Disabilities 1.50
Advances in Functional Transcriptomics: Linking Genetic Variation to RNA Processing 1.50
Application of Long Read Methods to Cancer Genomics 1.50
ASHG/ESHG Building Bridges Symposium: ASHG/ESHG Reconciling U.S. and European Guidelines on Variant Interpretation and Secondary Findings 1.50
Platform Presentations CME | P.A.C.E.® | NSGC
Machine Learning 1.50
Genetics and Functional Insights into Cardiovascular Disease 1.50
Disorders of Brain Development 1.50
Mechanisms of Gene Regulation in Cis and Trans 1.50
Novel Statistical Genetics Methods for Complex Traits 1.50
Strength in Diversity: Improving representation in study populations 1.50
Insights into Structural Variation Features in Constitutional Diseases and Cancer Genomes 1.50
Novel Genetic Factors for Cancer and Related Phenotypes 1.50
Rare Variants and Complex Disease 1.50
Natural Selection on Polygenic Traits and Omics 1.50
Single Cell Profiling in Disease, Development, and Distribution of Mutations 1.50
From Genes to Therapeutic Targets and Clinical Traits 1.50
Computational approaches for disease diagnosis and variant effect determination 1.50
Improving our understanding of the causes and consequences of cardiometabolic dysfunction 1.50
Molecular Mechanisms in Mendelian Disorders 1.50
Methods to Connect Gene Expression and Disease 1.50
Matchmaking and Mechanisms in Mendelian Disorders 1.50
Genetic Insights from Diverse Cohorts 1.50
Novel Biology from Large-Scale Genome Sequencing 1.50
Genome Discoveries from Long-Read Sequencing 1.50
Molecular Insights into Risk Factors and Mechanisms of Alzheimer Disease 1.50
Insights from Pediatric and Rare Disease Cohorts 1.50
Diverse Approaches in Analyses of Complex Disease 1.50
The Public Genome 1.50
Plenary Presentations CME | P.A.C.E.® | NSGC
Presidential Address: The Big Tent of Genetics/Genomics and Our World 0.50
Featured Plenary Session I 1.25
Featured Plenary Session II 1.25
Late Breaking COVID-19 Research Update 1.50
Featured Plenary Session III 1.25
Featured Plenary Session IV 1.25
Webinars OnDemand CME | P.A.C.E.® | NSGC
The Michigan Imputation Server: Data Preparation, Genotype Imputation, and Data Analysis 1.00
Interpreting genetic variation in clinical research using Ensembl: exploring Ensembl/GENCODE annotation, MANE transcripts and the Ensembl Variant Effect Predictor (VEP) 1.00
Clinical Genomics Education Boot Camp 1.00
GWAS analysis with Galaxy on the Analysis Visualization Integrated Lab-space (AnVIL) 1.00
Julia meets Mendel: Algorithms and software for modern genomic data analysis 1.00
The latest features and data types in the UCSC Genome Browser 1.00
RNA-seq for Mendelian disease diagnostics: A hands-on tutorial through bioinformatic tools and workflows 1.00
Integrating ENCODE data with your research: an interactive survey of ENCODE tools and resources 1.00
Variant prioritization with OpenCRAVAT 1.00
Find and analyze data in the cloud with Gen3, Dockstore and Terra 1.00


Learning Objectives

  • Describe the latest advances in the field of human genetics and genomics research.
  • Illustrate novel genetic findings from large population and clinical cohorts.
  • Describe computational modeling approaches for analysis of large genomic datasets to gain new functional insights.
  • Identify cutting edge pharmacogenetic research in racially/ethnically diverse populations.
  • Evaluate the effectiveness of disease modeling for understanding the genetic basis of disease.
  • Contrast the methods used to identify rare and common variants that predispose to cancer.
  • Indicate strategies for identifying molecular consequences of genetic variants.
  • Describe current and emerging technologies for studying genetic and genomic variation.
  • Demonstrate analytical approaches and tools for extracting novel biological information from genome sequencing in population cohorts.
  • Highlight challenges and opportunities in the functional annotation of loci associated with cardiovascular diseases.
  • Examine the impact of limited population diversity genomic studies on health disparities.
  • Understand the history and scope of GINA including its limitations and levels of protections.


To see the session presenters, please visit the online program planner.

Continuing Medical Education Credits (CMEs)*


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Medical Genetics and Genomics and the American Society of Human Genetics. The American College of Medical Genetics and Genomics is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The American College of Medical Genetics (ACMG) designates this enduring activity for a maximum of 74.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE (Continuing Education for non-physicians): This activity has been approved for CE credits.
*The certificate is accepted by the ABMGG for certification.


Access to the OnDemand sessions available beginning October 27, 2020.

There is a nonrefundable $50 fee payable during the registration process. If not purchased during registration, this fee can be paid by calling ASHG’s Registration Call Center at 774-247-4003. Course must be completed by the expiration date (October 25, 2021).

Continuing Education Unit Credits (CEUs) for Genetic Counselors

Credit Designation

This event has been submitted to the National Society of Genetic Counselors (NSGC) for approval of Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification. Approval for the requested CEUs and Contact Hours is currently pending.


Access to the OnDemand sessions available beginning October 27, 2020.

There is a nonrefundable $50 fee payable during the registration process. If not purchased during registration, this fee can be paid by calling ASHG’s Registration Call Center at 774-247-4003. If you would like a CEU certificate this year, the deadline to watch the OnDemand sessions for credit is Monday, November 30, 2020. The OnDemand sessions will be available for 12 months following the meeting. After November 30, you will receive your certificate in 2021. NSGC User IDs are required for all participants wishing to claim CEUs. Please use these instructions to find or create your NSGC User ID.

Genetic Counselors and Nurses should apply for CEUs. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of certification and recertification.

Continuing Education Unit Credits (CEUs) for California-Licensed Clinical and Molecular Laboratory Directors (P.A.C.E.®)

Credit Designation

Awaiting approval from the ASCLS P.A.C.E. ® Program, we anticipate offering up to 7.4 CEU credits or 74.00 contact hours for the on demand (self study) activity. The approved number of eligible credits/hours available for these activities will be posted on this web page in mid-September.


Access to the OnDemand sessions available beginning October 27, 2020.

There is a nonrefundable $50 fee payable during the registration process. If not purchased during registration, this fee can be paid by calling ASHG’s Registration Call Center at 774-247-4003. Course must be completed by the expiration date (October 25, 2021).

Clinical Laboratory Scientists should apply for P.A.C.E. CEUs. ABMGG will accept P.A.C.E. CEUs for diplomats participating in the MOC program in the following categories: Clinical Biochemical Geneticist, Clinical Cytogeneticist, and Clinical Molecular Geneticist.

ASHG CME Policies and Procedure

As a joint provider with the American College of Medical Genetics and Genomics accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Society of Human Genetics plans and implements all of its educational activities in accordance with the ACCME Essentials and Areas and ACCME® Policies to ensure balance, independence, objectivity and scientific rigor. In accordance with the ACCME® Standards for Commercial Support, everyone (speakers, moderators, platform presenters, all authors, committee members, and staff) who is in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit™ is required to disclose all financial relationships with any commercial interests (see definition below) within the past 12 months that creates a real or apparent conflict of interest. Individuals who do not disclose are disqualified from participating in a CME activity.

Individuals with potential for influence or control of CME content include:

  • planners, planning committee members, staff
  • authors
  • others who participate, e.g., facilitators and moderators

This disclosure pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services may be related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be resolved prior to the educational activity. Disclosure of off-label, experimental or investigational use of drugs or devices must also be made known to the audience.

ASHG’s Policy and Procedure for Identifying and Resolving Conflict of Interest for CME Educational Activities

The ACCME Standards of Commercial Support (SCS) describe six Standards: (1) independence (2) resolution of personal conflicts of interest (3) appropriate use of commercial support (4) appropriate management of associated commercial promotion (5) content and format without commercial bias and (6) disclosures relevant to potential commercial bias. These updated Standards underscore continued voluntary self-regulation by the CME community, ensuring that physicians have opportunities to engage in commercially unbiased life-long learning facilitated by accredited providers. The purpose of this policy is twofold: [1] to establish guidelines and a mechanism for identifying and resolving conflicts of interest in CME educational activities as required in Standard 2 (see below), and [2] to be consistent with ASHG’s policy for resolving conflicts of commitment and interest. Regardless of role, disclosure forms for speakers, moderators, all authors, program committee and staff participating in a CME activity will collected reviewed.

Standard 2: Resolution of Personal Conflicts of Interest in the Standards for Commercial Support requires the following of ACCME accredited providers:

  • Documenting that everyone who is in a position to control the content of an education activity has disclosed to the provider all relevant financial relationships with any commercial interests in any amount within the past 12 months that creates a conflict of interest. (SCS 2.1)
  • Disqualifying individuals who do not disclose from participating in a CME education activity. (SCS 2.2)
  • Identifying and resolving all conflicts of interest prior to the education activity. (SCS 2.3)

Terms as Defined by the ACCME:

  1. Commercial Interest: Any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. A commercial interest is not eligible for ACCME accreditation or participation in joint providership.
  2. Conflict of Interest: The ACCME considers financial relationships to create conflicts of interest in CME when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest. The potential for maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. See also “relevant financial relationships.”
  3. Financial Relationship: The ACCME requires anyone in control of CME content to disclose relevant financial relationships to the accredited provider. Individuals must also include in their disclosure the relevant financial relationships of a spouse or partner. The ACCME defines relevant financial relationships as financial relationships in any amount that create a conflict of interest and that occurred in the twelve-month period preceding the time that the individual was asked to assume a role controlling content of the CME activity. The ACCME has not set a minimal dollar amount – any amount, regardless of how small, creates the incentive to maintain or increase the value of the relationship. Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria for promotional speakers’ bureau, ownership interest (e.g. stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected. See also “conflict of interest.”
  4. Individuals with potential for influence or control of CME content: Planners and planning committee members, authors, teachers, educational activity director(s), educational partners(s), and others who participate, e.g. facilitators and moderators.

Please note: The ACCME has not a minimum dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

ASHG’s Procedures to Identify/Resolve Conflict

  • All individuals with potential for influence or control of content (defined in #2 above) must complete an ASHG’s Disclosure Form prior to the education activity as a condition of invitation and acceptance to participate. ASHG staff, Program Committee members are also required to complete an annual disclosure form.
  • An independent and unbiased assessment of content will be documented by one of the following methods to identify and resolve COIs –
    • Content review by the program planning committee.
    • Peer review committee are not participating in the specific educational activity.
    • Disclosures of all individuals participating in the educational activity will be made known to the audience as required by the ACCME, in addition to a disclosure of any COIs that have been resolved with independence and without bias.
    • Speakers will be required to verbally and include a disclosure slide (1st slide) identifying commercial relationships/interests or if none. Additionally, they must inform the audience prior to the presentation of any discussion of off-label use.

Consequences of Non-adherence to ACMG’s Policy

  • Disqualified from speaking if no disclosure form is completed (SCS 2.2)
  • Warning letter if the activity evaluation by the audience and session monitor comments indicates conflicts are present (1st occurrence)
  • Not invited to speak or participate in any other role in a ASHG CME-certified educational activity (2nd occurrence)

Content Validation and Fair Balance

  1. ASHG follows the ACCME policy on Content Validation for CME activities, which requires:
    1. All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.
    2. All scientific research referred to, reported, or used in CME in support or justification of patient care recommendations must conform to the generally accepted standards of experimental design, data collection, and analysis.
  2. Activities that fall outside the definition of CME/CE, “Educational activities that serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession” (source: ACCME and AMA), will not be certified for credit. CME activities that promote recommendations, treatment, or manners of practicing medicine or pharmacy that are not within the definition of CME/CE or, are known to have risks or dangers that outweigh the benefits or, are known to be ineffective in the treatment of patients.
  3. Presentations and CME/CE activity materials must give a balanced view of therapeutic options; use of generic names will contribute to this impartiality. If the CME/CE educational materials or content includes trade names, where available, trade names from several companies must be used.

Off-Label or Unapproved Use of Drugs or Devices

It is the policy of the ASHG to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) and the policy of the American Society of Human Genetics (ASHG), speakers and moderators presenting in sessions that offer CME and CEU credit must disclose, prior to the start of their presentations, the existence of any relevant financial interest and/or other relationship(s) they might have with the manufacturer(s) or provider(s) of any commercial product(s) or service(s), including diagnostic laboratories to be discussed during their presentation. These disclosures are included in the Online Program Planner.

Speakers with disclosures are required to provide a slide that states any relevant financial relationships (or lack thereof), and to state these to the audience at the start of their presentation. All disclosures have been peer reviewed by the ASHG Program subcommittee.

Diagnostic and Testing Labs and Commercial Interest

ASHG CME activities adhere to the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. The ACCME has defined under its conflict of interest definition the types of industry interests that must be excluded from CME content delivery. This largely applies to manufacturers of pharmaceuticals and devices. Diagnostic laboratories, whether not-for-profit or for-profit, that are not owned by device manufacturers are exempted from this CME requirement. However, they are still expected to be fair and balanced in their presentations.

HIPAA Compliance by Speakers

The ASHG supports medical information privacy. While the ASHG is not a “covered entity” under HIPAA 1996 and therefore is not required to meet these standards, ASHG wishes to take reasonable steps to ensure that the presentation of individually identifiable health information at ASHG-sponsored events has been properly authorized. All presenters have completed a form indicating whether they intend to present any form of individually identifiable healthcare information. If so, they were asked either to attest that a HIPAA-compliant consent form is on file at their institution, or to send ASHG a copy of the HIPAA compliance form. This information is on record at the ASHG Administrative Office and will be made available upon request.


The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of ASHG.


Contact ASHG

ASHG uses cookies to provide you with a secure and custom web experience. Privacy Policy